Skip to main content
. 2016 Dec 21;22(47):10304–10315. doi: 10.3748/wjg.v22.i47.10304

Table 6.

Study characteristics and outcomes of published randomized controlled trials of fecal microbial transplant for inflammatory bowel disease

Group Moayyedi et al (2015) Rossen et al (2015)
n (active/placebo) 75 (38/37) 48 (23/25)
Population Adult patients; Mild-moderate UC Adult patients; Mild-moderate UC
Active arm 50 mL enema (8 g healthy donor stool) 500 mL nasoduodenal infusion (120 g healthy donor stool)
Administered weekly × 6 wk Administered at week 0, 3
Control arm Normal saline Autologous FMT (patient’s stool)
Inclusion of patients on Biologics Yes, stable doses ≥ 12 wk No
Primary outcome Clinical remission (partial Mayo endoscopic score < 3 and Mayo endo score = 0) at week 7 Remission (SCCAI ≤ 2 + ≥ 1pt reduction in Mayo endoscopic score) at week 12
Clinical response (reduction in full Mayo score ≥ 3)
Results 9/38 (24%) treated with FMT vs 2/37 (5%) controls (P = 0.03) 7/23 (30%) treated with FMT vs 5/25 (20%) controls (P = 0.51)

Adapted from Grinspan et al[40] 2015. SCCAI: Simplified Clinical Colitis Activity Index.